{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Steinert&page=2",
    "query": {
      "condition": "Steinert",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Steinert&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T10:52:40.820Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03692312",
      "title": "Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Congenital Myotonic Dystrophy"
      ],
      "interventions": [
        {
          "name": "Tideglusib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AMO Pharma Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "6 Years to 16 Years"
      },
      "enrollment_count": 56,
      "start_date": "2021-03-03",
      "completion_date": "2023-04-04",
      "has_results": true,
      "last_update_posted_date": "2025-10-08",
      "last_synced_at": "2026-07-22T10:52:40.820Z",
      "location_count": 9,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 6 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03692312"
    },
    {
      "nct_id": "NCT07008469",
      "title": "Global Open-Label Extension Study of Del-desiran for the Treatment of DM1",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myotonic Dystrophy Type 1",
        "DM1",
        "Myotonic Dystrophy",
        "Myotonia",
        "Myotonic Dystrophy 1",
        "Myotonic Disorders",
        "Steinert Myotonic Dystrophy",
        "Steinert Disease"
      ],
      "interventions": [
        {
          "name": "Del-desiran (AOC 1001)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avidity Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 230,
      "start_date": "2025-07-25",
      "completion_date": "2030-10",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-07-22T10:52:40.820Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • Stanford, California • Denver, Colorado + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07008469"
    },
    {
      "nct_id": "NCT07505342",
      "title": "Remote Assessments and Genetic Determinants of Myotonic Dystrophy",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Myotonic Dystrophy Type 1 (DM1)",
        "DM1"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "88 Years",
        "sex": "ALL",
        "summary": "18 Years to 88 Years"
      },
      "enrollment_count": 1000,
      "start_date": "2022-05-10",
      "completion_date": "2030-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-07-22T10:52:40.820Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07505342"
    },
    {
      "nct_id": "NCT05004129",
      "title": "Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Congenital Myotonic Dystrophy"
      ],
      "interventions": [
        {
          "name": "Tideglusib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AMO Pharma Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "6 Years to 45 Years"
      },
      "enrollment_count": 76,
      "start_date": "2021-08-23",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-05-28",
      "last_synced_at": "2026-07-22T10:52:40.820Z",
      "location_count": 10,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 7 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05004129"
    },
    {
      "nct_id": "NCT07700225",
      "title": "Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "DM1",
        "Myotonic Dystrophy",
        "Myotonic Dystrophy 1",
        "Myotonic Dystrophy Type 1",
        "Myotonic Dystrophy Type-1",
        "Myotonic Dystrophy, Type 1 (DM1)",
        "Myotonic Muscular Dystrophy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 1000,
      "start_date": "2026-07",
      "completion_date": "2032-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-07-22T10:52:40.820Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07700225"
    },
    {
      "nct_id": "NCT04886518",
      "title": "Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myotonic Dystrophy 1",
        "Excessive Daytime Sleepiness"
      ],
      "interventions": [
        {
          "name": "Pitolisant Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Harmony Biosciences Management, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2021-06-28",
      "completion_date": "2024-10-31",
      "has_results": true,
      "last_update_posted_date": "2025-04-25",
      "last_synced_at": "2026-07-22T10:52:40.820Z",
      "location_count": 11,
      "location_summary": "Irvine, California • Aurora, Colorado • Tampa, Florida + 8 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04886518"
    },
    {
      "nct_id": "NCT00233519",
      "title": "Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myotonic Dystrophy"
      ],
      "interventions": [
        {
          "name": "SomatoKine/IPLEX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "21 Years to 60 Years"
      },
      "enrollment_count": 17,
      "start_date": "2005-11",
      "completion_date": "2008-05",
      "has_results": true,
      "last_update_posted_date": "2012-06-25",
      "last_synced_at": "2026-07-22T10:52:40.820Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00233519"
    },
    {
      "nct_id": "NCT06089018",
      "title": "Observational Study of Digital Biomarkers of Myotonia and Gait in Adults and Children With Myotonic Dystrophy",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Myotonic Dystrophy 1"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "12 Years to 90 Years"
      },
      "enrollment_count": 125,
      "start_date": "2022-09-10",
      "completion_date": "2024-09-10",
      "has_results": false,
      "last_update_posted_date": "2023-10-18",
      "last_synced_at": "2026-07-22T10:52:40.820Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06089018"
    },
    {
      "nct_id": "NCT06204809",
      "title": "Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myotonic Dystrophy 1"
      ],
      "interventions": [
        {
          "name": "PGN-EDODM1 for infusion",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "PepGen Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 24,
      "start_date": "2023-12-12",
      "completion_date": "2025-10-28",
      "has_results": false,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-07-22T10:52:40.820Z",
      "location_count": 7,
      "location_summary": "Irvine, California • Palo Alto, California • Atlanta, Georgia + 4 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06204809"
    },
    {
      "nct_id": "NCT07608432",
      "title": "Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy (DMD)",
        "Muscular Dystrophy, Duchenne",
        "Muscular Dystrophy (DMD)",
        "DMD",
        "Muscular Dystrophies",
        "Muscular Dystrophy in Children",
        "Muscular Dystrophy, Duchenne Type",
        "Muscular Dystrophy, Duchenne and Becker Types",
        "Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)",
        "Genetic Disease, Inborn",
        "Genetic Disease, X-Linked",
        "Congenital, Hereditary, and Neonatal Diseases and Abnormalities",
        "Neuromuscular Diseases (NMD)"
      ],
      "interventions": [
        {
          "name": "Zeleciment Rostudirsen (DYNE-251)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dyne Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "18 Years",
        "sex": "MALE",
        "summary": "4 Years to 18 Years · Male only"
      },
      "enrollment_count": 90,
      "start_date": "2026-06",
      "completion_date": "2032-10",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-07-22T10:52:40.820Z",
      "location_count": 1,
      "location_summary": "Hillsborough, North Carolina",
      "locations": [
        {
          "city": "Hillsborough",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07608432"
    }
  ]
}